CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Chen Y, Bi F, An Y, et al. Coexpression network analysis identified Krüppel-like factor 6 (KLF6) association with chemosensitivity in ovarian cancer. J Cell Biochem. 2019;120:2607–2615.
   PubMed Web of Science ®Google Scholar
• Doherty JA, Peres LC, Wang C, et al. Challenges and opportunities in studying the epidemiology of ovarian cancer subtypes. Curr Epidemiol Rep. 2017;4(3):211–220. doi:10.1007/s40471-017-0115-y
   PubMedGoogle Scholar
• Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42(7):918–931. doi:10.1016/j.humpath.2011.03.003
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747. doi:10.1016/j.ajpath.2015.11.011
   PubMed Web of Science ®Google Scholar
• Moschetta M, Boussios S, Rassy E, et al. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann Transl Med. 2020;8(24):1710. doi:10.21037/atm-20-1683
   PubMed Web of Science ®Google Scholar
• Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–1145. doi:10.1002/ijc.27711
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. doi:10.1038/nm0603-669
   PubMed Web of Science ®Google Scholar
• Chester C, Dorigo O, Berek JS, et al. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer. 2015;3(1):7. doi:10.1186/s40425-015-0051-7
   PubMed Web of Science ®Google Scholar
• Hollingsworth HC, Kohn EC, Steinberg SM, et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147(1):33–41.
   PubMed Web of Science ®Google Scholar
• Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178–187. doi:10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi:10.1056/NEJMoa1104390
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A Phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496. doi:10.1056/NEJMoa1103799
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308. doi:10.1200/JCO.2013.51.4489
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–3421. doi:10.1172/JCI80008
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi:10.1038/nri3405
   PubMed Web of Science ®Google Scholar
• Chen H, Chong W, Wu Q, et al. Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades. Front Immunol. 2019;10:1113. doi:10.3389/fimmu.2019.01113
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Chen Z, et al. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):p. 193. doi:10.1186/s13046-019-1192-1
   Web of Science ®Google Scholar
• Birkbak NJ, Kochupurakkal B, Izarzugaza JMG, et al. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013;8(11):e80023. doi:10.1371/journal.pone.0080023
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi:10.1086/375033
   PubMed Web of Science ®Google Scholar
• Stratton JF, Thompson D, Bobrow L, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet. 1999;65(6):1725–1732. doi:10.1086/302671
   PubMed Web of Science ®Google Scholar
• Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009;3(2):97–137.
   PubMed Web of Science ®Google Scholar
• Zhai QJ, Lu K, Liu J, et al. Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific. Int J Clin Exp Pathol. 2008;1(6):502–509.
   PubMed Web of Science ®Google Scholar
• Meindl A, Ditsch N, Kast K, et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int. 2011;108(19):323–330.
   PubMed Web of Science ®Google Scholar
• Clague J, Wilhoite G, Adamson A, et al. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One. 2011;6(9):e25632. doi:10.1371/journal.pone.0025632
   PubMed Web of Science ®Google Scholar
• Song H, Ramus SJ, Kjaer SK, et al. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One. 2007;2(3):e268. doi:10.1371/journal.pone.0000268
   PubMed Web of Science ®Google Scholar
• Kuusisto KM, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13(1):R20. doi:10.1186/bcr2832
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020;38(1):181–193. doi:10.1007/s10637-019-00867-4
   PubMed Web of Science ®Google Scholar
• Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437–1447. doi:10.1093/annonc/mdz192
   PubMed Web of Science ®Google Scholar
• Boussios S, Karathanasi A, Cooke D, et al. PARP inhibitors in ovarian cancer: the route to “Ithaca”. Diagnostics. 2019;9(2):55.
   Web of Science ®Google Scholar
• Bi F, Chen Y, Yang Q. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int. 2020;20(1):373. doi:10.1186/s12935-020-01472-9
   PubMed Web of Science ®Google Scholar
• Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–198. doi:10.1016/j.ygyno.2011.09.039
   PubMed Web of Science ®Google Scholar
• Lau WL, Scholnick SB. Identification of two new members of the CSMD gene family. Genomics. 2003;82(3):412–415. doi:10.1016/S0888-7543(03)00149-6
   PubMed Web of Science ®Google Scholar
• Shimizu A, Asakawa S, Sasaki T, et al. A novel giant gene CSMD3 encoding a protein with CUB and sushi multiple domains: a candidate gene for benign adult familial myoclonic epilepsy on human chromosome 8q23.3-q24.1. Biochem Biophys Res Commun. 2003;309(1):143–154. doi:10.1016/S0006-291X(03)01555-9
   PubMed Web of Science ®Google Scholar
• Oeschger FM, Wang WZ, Lee S, et al. Gene expression analysis of the embryonic subplate. Cerebral Cortex. 2012;22(6):1343–1359. doi:10.1093/cercor/bhr197
   PubMed Web of Science ®Google Scholar
• Magri C, Sacchetti E, Traversa M, et al. New copy number variations in schizophrenia. PLoS One. 2010;5(10):e13422. doi:10.1371/journal.pone.0013422
   PubMed Web of Science ®Google Scholar
• Malhotra D, McCarthy S, Michaelson J, et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011;72(6):951–963. doi:10.1016/j.neuron.2011.11.007
   PubMed Web of Science ®Google Scholar
• Curran S, Ahn JW, Grayton H, et al. NRXN1 deletions identified by array comparative genome hybridisation in a clinical case series - further understanding of the relevance of NRXN1 to neurodevelopmental disorders. J Mol Psychiatry. 2013;1(1):4. doi:10.1186/2049-9256-1-4
   PubMedGoogle Scholar
• Wolff RK, Hoffman MD, Wolff EC, et al. Mutation analysis of adenomas and carcinomas of the colon: early and late drivers. Genes Chromosomes Cancer. 2018;57(7):366–376. doi:10.1002/gcc.22539
   PubMed Web of Science ®Google Scholar
• Li C, Gao Z, Li F, et al. Whole exome sequencing identifies frequent somatic mutations in cell-cell adhesion genes in Chinese patients with lung squamous cell carcinoma. Sci Rep. 2015;5:14237. doi:10.1038/srep14237
   PubMed Web of Science ®Google Scholar
• Qiu Z, Lin A, Li K, et al. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer. Drug Des Devel Ther. 2019;13:2021–2041. doi:10.2147/DDDT.S205633
   PubMed Web of Science ®Google Scholar
• Gaboriaud C, Gregory-Pauron L, Teillet F, et al. Structure and properties of the Ca(2+)-binding CUB domain, a widespread ligand-recognition unit involved in major biological functions. Biochem J. 2011;439(2):185–193. doi:10.1042/BJ20111027
   PubMed Web of Science ®Google Scholar
• Nakayama M, Hama C. Modulation of neurotransmitter receptors and synaptic differentiation by proteins containing complement-related domains. Neurosci Res. 2011;69(2):87–92. doi:10.1016/j.neures.2010.11.006
   PubMed Web of Science ®Google Scholar
• Gunnersen JM, Kim MH, Fuller SJ, et al. Sez-6 proteins affect dendritic arborization patterns and excitability of cortical pyramidal neurons. Neuron. 2007;56(4):621–639. doi:10.1016/j.neuron.2007.09.018
   PubMed Web of Science ®Google Scholar
• Chen G, Sima J, Jin M, et al. Semaphorin-3A guides radial migration of cortical neurons during development. Nat Neurosci. 2008;11(1):36–44. doi:10.1038/nn2018
   PubMed Web of Science ®Google Scholar
• Sia GM, Clem RL, Huganir RL. The human language-associated gene SRPX2 regulates synapse formation and vocalization in mice. Science. 2013;342(6161):987–991. doi:10.1126/science.1245079
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li H, Mao Y, et al. Apoptotic SKOV3 cells stimulate M0 macrophages to differentiate into M2 macrophages and promote the proliferation and migration of ovarian cancer cells by activating the ERK signaling pathway. Int J Mol Med. 2020;45(1):10–22.
   PubMed Web of Science ®Google Scholar
• Yunna C, Mengru H, Lei W, et al. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090. doi:10.1016/j.ejphar.2020.173090
   PubMed Web of Science ®Google Scholar
• Terzic J, Seipel A, Dubuisson J, et al. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. Gynecol Oncol Rep. 2020;33:100600. doi:10.1016/j.gore.2020.100600
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885–900.e10. doi:10.1016/j.ccell.2019.05.004
   PubMed Web of Science ®Google Scholar